Jon B Rousseau

Jon B Rousseau sold 260,000 shares (260.0K) at $58.75 for $15,275,000.00 at BTSG on 2026-06-05

Jon B Rousseau executed 2 separate sales totaling 260,000 shares for $15,275,000.00 at a blended average price of $58.75 on 2026-06-05, eliminating his non-derivative holdings in the transaction. The stock currently trades at $57.40, down 7.6% from its 52-week high of $62.11. Rousseau's cross-ticker track record shows 3 prior sells with an average 90-day return of +36.0% and a 0.00% well-timed rate, indicating his prior sales at other tickers were followed by stock appreciation. At BTSG specifically, his 5 prior trades show a 2 of 5 well-timed pattern at the 90-day mark, with his most recent sale on 2026-03-04 followed by a +44.2% 90-day return. The transaction occurs as BTSG trades near its 52-week high range and after strong recent momentum (+38.4% over 90 days). Derivative holdings remain post-transaction (1,166,064 stock options directly and 404,676 through The Margaret Rousseau Children Trust), so this represents a sale of a specific batch rather than a complete position exit.

Jon B. Rousseau sells 220,000 BTSG shares at $41.15; retains 1.21M post-sale amid recent +11.3% 30-day rally

Jon B. Rousseau sold 220,000 shares (220.0K shares) of BrightSpring Health Services at $41.15 on 2026-03-04, reducing his position to 1,210,725 shares (1.21M shares) from 1,430,725 shares (1.43M shares), a reduction of -15.4% of pre-transaction holdings. The stock has appreciated 11.3% over the prior 30 days and 15.9% over the prior 90 days, trading at $41.49 current price and within 1.1% of its 52-week high of $41.96. Rousseau's prior two sales across all tickers averaged a 90d return of +31.8% (poorly timed, as the stock rose post-sale), while his prior three sales at BTSG specifically show mixed timing: two generated 90d returns of +34.6% and +29.1% (poorly timed), but his timing pattern at this ticker stands at 3 of 5 prior trades well-timed. This sale occurs as the company shows solid fundamentals with $3.3B in latest quarterly revenue, +14.6% annual growth, and a P/E of 23.71, leaving limited obvious operational deterioration to explain the reduction.

BTSG insider Rousseau sells 235,000 shares at $28.78, reducing holdings 17.2%; stock now at 52-week high of $32.94

Jon B. Rousseau sold 235,000 shares (235.0K shares) of BrightSpring Health Services (BTSG) at $28.78 on 2025-10-22, reducing his holdings from 1,366,930 shares (1.37M shares) to 1,131,930 shares (1.13M shares). The stock has since appreciated to its 52-week high of $32.94, representing a -12.6% gap between transaction price and current price. Across his prior trades at this ticker, Rousseau has a mixed record: his three earlier buys in March 2024 showed strong 90-day performance (+31.4% to +33.5%), while his June 2025 sell at a lower price resulted in a +29.1% gain over 90 days—indicating that sell was poorly timed relative to subsequent price appreciation. The present transaction occurs as the stock trades at elevated valuation (P/E of 89.03) and the company carries significant fundamental headwinds: negative full-year net income despite +27.6% annual revenue growth, suggesting profitability challenges despite sales expansion.

BTSG insider Jon B Rousseau sells 531.8K shares (31.0% of holdings) at $21.75; stock down 9.8% in 30 days.

Jon B Rousseau sold 531,840 shares of BrightSpring Health Services at $21.75 on 2025-06-12, representing a 31.0% reduction in his stake from 1,715,973 to 1,184,133 shares. The transaction occurred as the stock trades at $21.18 (current), down 9.8% over 30 days despite showing 21.6% gains over 90 days and trading 13.3% below its 52-week high of $24.43. Notably, Rousseau's prior three BTSG purchases (all in March 2024) demonstrated strong execution timing, with 90-day returns of +31.4%, +31.4%, and +33.5% respectively. The sale timing relative to forward performance is not yet measurable. Fundamentals show a conflicted picture: the company posted $2.9B quarterly revenue with 27.6% annual growth, but reported negative full-year net income and carries a high 64.18 P/E ratio despite $29.5M profit in the latest quarter.